Showing results (51-60 of 83) with videos related to
Sort By:
Pageof 9
The British Journal of Radiology|February 5, 2021
Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue typesSarah Denzler, Diem Vuong, Marta Bogowicz, et al.Cancer Chemotherapy and Pharmacology|August 25, 2019
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN studySacha I Rothschild, Daniel Betticher, Reinhard Zenhäusern, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2015
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, et al.Lung Cancer (Amsterdam, Netherlands)|November 6, 2012
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528Oliver Gautschi, Anne-Marie Dingemans, Susanne Crowe, et al.Lung Cancer (Amsterdam, Netherlands)|September 27, 2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05)Francesco Zappa, Cornelia Droege, Daniel Betticher, et al.Clinical Lung Cancer|December 21, 2016
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 TrialOliver Gautschi, Sacha I Rothschild, Qiyu Li, et al.Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.The Lancet. Oncology|October 13, 2022
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trialAlexandros Papachristofilou, Jens Bedke, Stefanie Hayoz, et al.Antiviral Therapy|October 12, 2007
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort StudyMathew Simcock, Monika Blasko, Urs Karrer, et al.Pageof 9